1.90
+0.0064(+0.34%)
Currency In USD
| Previous Close | 1.89 |
| Open | 1.89 |
| Day High | 1.92 |
| Day Low | 1.81 |
| 52-Week High | 2.27 |
| 52-Week Low | 0.77 |
| Volume | 1.89M |
| Average Volume | 2.27M |
| Market Cap | 199.69M |
| PE | -6.32 |
| EPS | -0.3 |
| Moving Average 50 Days | 1.73 |
| Moving Average 200 Days | 1.48 |
| Change | 0.01 |
If you invested $1000 in SELLAS Life Sciences Group, Inc. (SLS) 10 years ago, it would be worth $0.04 as of October 07, 2025 at a share price of $1.896. Whereas If you bought $1000 worth of SELLAS Life Sciences Group, Inc. (SLS) shares 5 years ago, it would be worth $692.12 as of October 07, 2025 at a share price of $1.896.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
SELLAS Life Sciences Group to Host Virtual R&D Day on October 29, 2025: Advancing Novel Therapies in Acute Myeloid Leukemia (AML): An Overview of the Ongoing Phase 3 REGAL Trial of Galinpepimut-S (GPS) and SLS009 Program Update
GlobeNewswire Inc.
Sep 30, 2025 12:30 PM GMT
NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indic
SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $23.6 Million in Gross Proceeds
GlobeNewswire Inc.
Sep 11, 2025 12:30 PM GMT
NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indic
SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification
GlobeNewswire Inc.
Aug 07, 2025 12:30 PM GMT
- Final Analysis Anticipated by Year-End Upon Occurrence of 80 Events - NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical c